By Najat Kantouar and Helena SmolakGSK's experimental drug for asthma met its goals in the latest trial, moving a treatment with potential annual peak sales of more than 3 billion pounds ($3.81 billion) closer to market. The British pharmaceutical company's depemokimab drug reduced asthma attacks in late-stage trials for patients with severe eosinophilic asthma, a form of the disease caused by high levels of white blood cells, GSK said Tuesday. Depemokimab could be the first approved drug to allow a long-term dosing interval, requiring only two injections a year. GSK plans to submit the drug for approval for severe asthma in the U.S. in the second half of the year. It expects depemokimab results on further treatments for a range of related respiratory conditions, which are also in late-stage trials.

Source: Wall Street Journal May 21, 2024 12:16 UTC